Pharma companies set for strong performance in March 2025 quarter amid earning weakness

Pharma companies are expected to shine in the March 2025 quarter, offering stability amid a broader slowdown in earnings. Based on the average estimates from four brokerages, Sun Pharmaceutical, Dr. Reddy's Laboratories, and Lupin are poised for strong growth, supported by robust U.S. portfolios and steady domestic performance. Meanwhile, Cipla and Torrent Pharmaceuticals are likely to remain resilient despite margin pressures, and Divi's Laboratories is projected to deliver moderate gains 0

.